Disc Medicine director granted 5,176 stock options

Disc Medicine director Nadim Ahmed received a grant of stock options, giving him the right to buy 5,176 shares of common stock.

Rhea-AI Filing Summary

Disc Medicine director Nadim Ahmed received a grant of stock options, giving him the right to buy 5,176 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036.

These options vest on the earlier of the company’s 2027 annual stockholders’ meeting or the one-year anniversary of the grant date, contingent on his continued board service. After this grant, Ahmed holds options covering 5,176 shares directly.

Insider Trade Summary

Grant/Award: 5,176 shares

Grant/Award 1 txn

Insider AHMED NADIM

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,176	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,176 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 5,176 shares Exercise price: $70.79 per share Expiration date: June 17, 2036 +1 more

4 metrics

Options granted 5,176 shares Stock Option (Right to Buy) grant to director

Exercise price $70.79 per share Exercise price of granted stock options

Expiration date June 17, 2036 Option expiration for this grant

Post-grant option holdings 5,176 options Total options reported following transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of its stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 70.7900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-17T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of its stockholders financial

"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders"

vest financial

"The shares underlying this option vest upon the first to occur"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Disc Medicine (IRON) director Nadim Ahmed receive in this Form 4 filing?

Director Nadim Ahmed received a grant of stock options covering 5,176 shares of Disc Medicine common stock, with an exercise price of $70.79 per share and an expiration date of June 17, 2036, according to the Form 4 disclosure.

At what price can Nadim Ahmed exercise his Disc Medicine (IRON) stock options?

The stock options granted to Nadim Ahmed are exercisable at $70.79 per share. This exercise price is fixed in the award and applies to all 5,176 underlying shares of Disc Medicine common stock disclosed in the Form 4.

When do Nadim Ahmed’s Disc Medicine (IRON) stock options vest?

The options vest on the earlier of Disc Medicine’s 2027 annual stockholders’ meeting or the one-year anniversary of the grant date. Vesting is conditioned on Ahmed’s continued service as a director through that vesting date, as described in the footnote.

How many Disc Medicine (IRON) options does Nadim Ahmed hold after this transaction?

After this grant, Nadim Ahmed beneficially holds stock options for 5,176 shares of Disc Medicine common stock. The Form 4 shows these options as directly owned and reflects the post-transaction total for this specific award.

Is Nadim Ahmed’s Form 4 transaction a market purchase or sale of Disc Medicine (IRON) shares?

The Form 4 reports a grant of stock options, not an open-market purchase or sale. The transaction is coded as an “A” award, representing a compensation-related acquisition of derivative securities rather than buying or selling common stock in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AHMED NADIM

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$70.79	06/18/2026		A		5,176		(1)	06/17/2036	Common Stock	5,176	$0	5,176	D

Explanation of Responses:

1. The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)